Source map — Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Every domain this feed has drawn corroborated signal from. We store facts and short excerpts and link back to originals — never republished article bodies.
| Source | Type | Trust |
|---|---|---|
| The Guardian | news | 60% |
| Scientific American | news | 60% |
| Eli Lilly | news | 60% |
| Reuters | news | 60% |
| WSJ | news | 60% |
| CNBC | news | 60% |
| BioPharma Dive | news | 60% |
| Medscape | news | 60% |
| Simply Wall Street | news | 60% |
| ScienceAlert | news | 60% |
| www.cnbc.com | news | 50% |
| www.fool.com | news | 50% |
| longbridge.com | news | 50% |
| biotech-insider.com | news | 50% |
| dispatchtimes.com | news | 50% |
| medicalxpress.com | news | 50% |